ArticleSTAR*D What Have We Learned Thus Far?Gilmer, William S. MD; Kemp, David E. MD Author Information Dr. Gilmer is Associate Professor of Psychiatry and Behavioral Sciences, Asher Center for the Study and Treatment of Depressive Disorders, Northwestern University Feinberg School of Medicine, 446 E. Ontario, Suite 7-100, Chicago, IL 60611; E-mail: [email protected]; and Dr. Kemp is Research Fellow, Bipolar Disorder Research Center, Case Western Reserve School of Medicine, Cleveland, OH. Dr. Gilmer has disclosed that he is/was the recipient of grant/research support from Forest, Janssen, Neuronetics, and Aspect; is/was a consultant/advisor for Pfizer, Forest, GlaxoSmithKline, and Astra Zeneca; and was a stock shareholder of Pfizer. Dr. Kemp has disclosed that he was the recipient of grant/research support from Abbott Laboratories, Bristol-Myers Squibb, and GlaxoSmithKline. The authors have disclosed that the use of buspirone has not been approved by the U.S. Food and Drug Administration for the treatment of depression. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study is supported by federal funds from the National Institute of Mental Health under contract N01 MH-90003 to the University of Texas Southwestern Medical Center at Dallas (A.J. Rush, principal investigator). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. International Drug Therapy Newsletter: October 2006 - Volume 41 - Issue 10 - p 75-82 Buy CME Test © 2006 Lippincott Williams & Wilkins, Inc.